GB2213484B - New derivatives of 17beta-oh 19-nor steroids substituted in the 17 alpha position, their preparation, their use as medicaments and pharmaceutical compositions - Google Patents

New derivatives of 17beta-oh 19-nor steroids substituted in the 17 alpha position, their preparation, their use as medicaments and pharmaceutical compositions

Info

Publication number
GB2213484B
GB2213484B GB8830380A GB8830380A GB2213484B GB 2213484 B GB2213484 B GB 2213484B GB 8830380 A GB8830380 A GB 8830380A GB 8830380 A GB8830380 A GB 8830380A GB 2213484 B GB2213484 B GB 2213484B
Authority
GB
United Kingdom
Prior art keywords
17beta
medicaments
preparation
pharmaceutical compositions
alpha position
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
GB8830380A
Other languages
English (en)
Other versions
GB8830380D0 (en
GB2213484A (en
Inventor
Martine Moguilewsky
Lucien Nedelec
Francois Nique
Daniel Philibert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8718376A external-priority patent/FR2625505B2/fr
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Publication of GB8830380D0 publication Critical patent/GB8830380D0/en
Publication of GB2213484A publication Critical patent/GB2213484A/en
Application granted granted Critical
Publication of GB2213484B publication Critical patent/GB2213484B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB8830380A 1987-12-30 1988-12-30 New derivatives of 17beta-oh 19-nor steroids substituted in the 17 alpha position, their preparation, their use as medicaments and pharmaceutical compositions Expired - Lifetime GB2213484B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8718376A FR2625505B2 (fr) 1981-01-09 1987-12-30 Nouveaux derives steroides substitues en 11beta leur procede de preparation et leur application comme medicaments et les compositions pharmaceutiques les renfermant

Publications (3)

Publication Number Publication Date
GB8830380D0 GB8830380D0 (en) 1989-03-01
GB2213484A GB2213484A (en) 1989-08-16
GB2213484B true GB2213484B (en) 1991-10-09

Family

ID=9358447

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8830380A Expired - Lifetime GB2213484B (en) 1987-12-30 1988-12-30 New derivatives of 17beta-oh 19-nor steroids substituted in the 17 alpha position, their preparation, their use as medicaments and pharmaceutical compositions

Country Status (14)

Country Link
US (1) US5006518A (en:Method)
JP (1) JP2785023B2 (en:Method)
AT (1) AT396787B (en:Method)
BE (1) BE1004905A4 (en:Method)
CA (1) CA1303025C (en:Method)
CH (1) CH676852A5 (en:Method)
DE (1) DE3844408C2 (en:Method)
ES (1) ES2012197A6 (en:Method)
GB (1) GB2213484B (en:Method)
GR (1) GR880100868A (en:Method)
IT (1) IT1235358B (en:Method)
LU (1) LU87417A1 (en:Method)
NL (1) NL8803196A (en:Method)
SE (1) SE503267C2 (en:Method)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2654337B1 (fr) * 1989-11-15 1994-08-05 Roussel Uclaf Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
DE4042004A1 (de) * 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
EP0496520A1 (en) * 1991-01-22 1992-07-29 Merck & Co. Inc. Novel bone acting agents
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5639598A (en) * 1994-05-19 1997-06-17 The Trustees Of The University Of Pennsylvania Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
DE69500542T2 (de) * 1994-05-19 1998-01-02 Akzo Nobel Nv 11,21-Bisphenyl-19-nor-pregnan Derivate
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
JP2001301596A (ja) 2000-04-19 2001-10-31 Sumitomo Denko Brake Systems Kk 車両用液圧ブレーキシステムの制御方法
BRPI0803102A2 (pt) * 2007-05-01 2011-11-01 Sicor Inc um processo para preparar drospirenona e intermediários da mesma
PL2576582T3 (pl) 2010-05-26 2020-06-29 Corcept Therapeutics, Inc. Leczenie dystrofii mięśniowej
EP3265127B1 (en) 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
SG11201707525TA (en) 2015-03-30 2017-10-30 Corcept Therapeutics Inc Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
ES2865334T3 (es) 2015-08-13 2021-10-15 Corcept Therapeutics Inc Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH
WO2017112909A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11124537B2 (en) 2015-12-23 2021-09-21 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
AU2017210156B2 (en) 2016-01-19 2021-10-28 Corcept Therapeutics, Inc. Differential diagnosis of Ectopic Cushing's Syndrome
SI3523315T1 (sl) 2016-10-07 2021-08-31 Oric Pharmaceuticals, Inc. Inhibitor glukokortikoidnega receptorja
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
WO2018236749A2 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
WO2022130015A2 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0057115A2 (fr) * 1981-01-09 1982-08-04 Roussel-Uclaf Nouveaux dérivés stéroides substitués en 11beta, procédé de préparation, leur application comme médicament et les compositions les renfermant
EP0110434A1 (fr) * 1981-01-09 1984-06-13 Roussel-Uclaf Nouveaux produits intermédiaires stéroides substitués en 11-beta et procédé de préparation de ces produits
EP0129499A2 (de) * 1983-06-15 1984-12-27 Schering Aktiengesellschaft 13alpha-Alkylgonane, deren Herstellung und diese enthaltende pharmazeutische Präparate
EP0196707A1 (fr) * 1982-06-11 1986-10-08 Roussel-Uclaf Nouveaux 19-nor stéroides substitués en 11, en 17 et éventuellement en 2, leur préparation, leur application comme médicaments, les compositions les renfermant et les nouveaux intermédiaires obtenus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
DE3461090D1 (en) * 1983-02-18 1986-12-04 Schering Ag 11-beta-aryl-estradienes, process for their preparation and pharmaceutical compositions containing them
FR2549067B1 (fr) * 1983-06-14 1985-12-27 Roussel Uclaf Derives estradieniques radioactifs marques au tritium, leur procede de preparation et leur application pour l'etude et le dosage radio-immunologique de steroides dans les fluides biologiques
US4780461A (en) * 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2566779B2 (fr) * 1984-06-29 1987-03-06 Roussel Uclaf Nouveaux derives steroides substitues en 11b, leur procede de preparation et leur application comme medicaments
DE3506785A1 (de) * 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3619413C2 (de) * 1986-06-10 2000-04-06 Schering Ag 9alpha, 10alpha-Methylen-Estrene, deren Herstellung und diese enthaltende pharmazeutische Präparate
DE3625315A1 (de) * 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) * 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
IE60780B1 (en) * 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0057115A2 (fr) * 1981-01-09 1982-08-04 Roussel-Uclaf Nouveaux dérivés stéroides substitués en 11beta, procédé de préparation, leur application comme médicament et les compositions les renfermant
US4447424A (en) * 1981-01-09 1984-05-08 Roussel Uclaf Steroid derivatives
EP0110434A1 (fr) * 1981-01-09 1984-06-13 Roussel-Uclaf Nouveaux produits intermédiaires stéroides substitués en 11-beta et procédé de préparation de ces produits
US4634695A (en) * 1981-01-09 1987-01-06 Roussel Uclaf Steroid derivatives
EP0196707A1 (fr) * 1982-06-11 1986-10-08 Roussel-Uclaf Nouveaux 19-nor stéroides substitués en 11, en 17 et éventuellement en 2, leur préparation, leur application comme médicaments, les compositions les renfermant et les nouveaux intermédiaires obtenus
EP0129499A2 (de) * 1983-06-15 1984-12-27 Schering Aktiengesellschaft 13alpha-Alkylgonane, deren Herstellung und diese enthaltende pharmazeutische Präparate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CA 106 (16) : 129694R *

Also Published As

Publication number Publication date
BE1004905A4 (fr) 1993-02-23
GR880100868A (el) 1994-03-31
ATA318788A (de) 1993-04-15
ES2012197A6 (es) 1990-03-01
IT8848730A0 (it) 1988-12-29
JP2785023B2 (ja) 1998-08-13
US5006518A (en) 1991-04-09
GB8830380D0 (en) 1989-03-01
SE8804692L (sv) 1989-07-01
DE3844408A1 (de) 1989-07-13
LU87417A1 (fr) 1989-06-14
JPH01213296A (ja) 1989-08-28
CA1303025C (fr) 1992-06-09
SE8804692D0 (sv) 1988-12-29
GB2213484A (en) 1989-08-16
DE3844408C2 (de) 2001-07-26
SE503267C2 (sv) 1996-04-29
CH676852A5 (en:Method) 1991-03-15
NL8803196A (nl) 1989-07-17
AT396787B (de) 1993-11-25
IT1235358B (it) 1992-06-30

Similar Documents

Publication Publication Date Title
GB2213484B (en) New derivatives of 17beta-oh 19-nor steroids substituted in the 17 alpha position, their preparation, their use as medicaments and pharmaceutical compositions
NZ219776A (en) 11-substituted steroid 17, 2'-furan derivatives and pharmaceutical compositions
ZA83982B (en) 3-ceto delta 4,9 19-nor steroid derivatives,their preparation their use as medicaments,the compositions containing them and the intermediates thus obtained
IL85767A0 (en) Benzoxazole derivatives,their preparation and pharmaceutical compositions containing them
IL91129A0 (en) Aminomethyloxooxazolidinyl arylbenzene derivatives,their preparation and pharmaceutical compositions containing them
IL90245A0 (en) Ethenediamine derivatives,their preparation and pharmaceutical compositions containing them
IL86798A (en) 2,2-dimethylchroman-3-ol derivatives, their preparation and pharmaceutical compositions containing them
IL88989A (en) 16-dehydro-vitamin d3 derivatives, their preparation and pharmaceutical compositions containing them
IL93124A0 (en) Benzocycloalkenyldihydroxyalkanoic-acid derivatives,their preparation and pharmaceutical compositions
PT86407A (en) Process for the preparation of new alkanesulfonanilide derivatives and pharmaceutical compositions comprising the same
IL89778A (en) Unsaturated n-benzopyranyllactams, their preparation and pharmaceutical compositions containing them
HU896479D0 (en) Process for the preparation of capsaycin derivatives and pharmaceutical compositions thereof
HU896612D0 (en) Process for the preparation of 2-iminebenzothiazole derivatives and pharmaceutical compositions thereof
AU8316587A (en) Pharmaceutical compositions and their use
IL88002A0 (en) 2,2-dimethylchromene derivatives,their preparation and pharmaceutical compositions containing them
PH24239A (en) New 4-pyridone derivatives,their pharmaceutical compositions and use
IL92268A0 (en) 14alpha,17alpha,ethanoestratriene derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
IL91245A0 (en) Benzopyranol derivatives,their preparation and pharmaceutical compositions containing them
IL90002A0 (en) Phosphonoalkylpurine derivatives,their preparation and pharmaceutical compositions containing them
IL90231A0 (en) 1,1-dioxo-cephem-4-carbothiolic acid derivatives,their preparation and pharmaceutical compositions containing them
IL87016A (en) Phenylpiperidine derivatives, their preparation and pharmaceutical compositions containing them
IL93478A0 (en) Steroid diols,pharmaceutical compositions containing them and their preparation
DE2860691D1 (en) 1,2,4-oxadiazol derivatives, their preparation and application in pharmaceutical compositions
PT83984A (en) Process for the preparation of novel 16,17-acetalsubstituted pregnane 21-oic derivatives and of pharmaceutical compositions containing the same
IL82294A0 (en) 1,3-dihydropyridine derivatives,process for the preparation thereof and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Expiry date: 20081229